Surotomycin versus vancomycin in adults with Clostridium difficile infection: Primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 12, 2017, Pages 3462-3470

  Daley, P ^a   Louie, T ^b   Lutz, J E ^c   Khanna, S ^d   Stoutenburgh, U ^e   Jin, M ^e   Adedoyin, A ^e   Chesnel, L ^e   Guris, D ^e   Larson, K B ^e   Murata, Y ^e  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c St Charles Health System   (United States)

^d MAYO CLINIC   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLACEBO; SUROTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CB-183,315; CYCLOPEPTIDE; LIPOPEPTIDE;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD LEVEL; CLINICAL OUTCOME; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PHARMACOKINETIC PARAMETERS; PHASE 3 CLINICAL TRIAL; PRIMARY INFECTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; ADOLESCENT; CLINICAL TRIAL; CLOSTRIDIUM INFECTION; COMPARATIVE STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM INFECTIONS; DOUBLE-BLIND METHOD; HUMANS; LIPOPEPTIDES; MIDDLE AGED; PEPTIDES, CYCLIC; PLACEBOS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 85042181910     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx299     Document Type: Article

References (28)

1. Reveles KR, Lee GC, Boyd NK et al. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010. Am J Infect Control 2014; 42: 1028-32
2. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55 Suppl 2: S65-70
3. Kelly CP, Lamont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008; 359: 1932-40
4. O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136: 1913-24
5. Lessa FC, Mu Y, BambergWMet al. Burden of Clostridiumdifficile infection in the United States.NEngl JMed2015; 372: 825-34
6. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 373: 287-8
7. Mullane KM, Gorbach S. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther 2011; 9: 767-77
8. Louie TJ, Cannon K, Byrne B et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55 Suppl 2: S132-42
9. Wenisch C, Parschalk B, Hasenhundl M et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813-8
10. Petrella LA, Sambol SP, Cheknis A et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012; 55: 351-7
11. AlamMZ, Wu X, Mascio C et al. Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile. Antimicrob Agents Chemother 2015; 59: 5165-70
12. Mascio CT, Mortin LI, Howland KT et al. In vitro and in vivo characterization of CB-183, 315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 2012; 56: 5023-30
13. Mascio CT, Chesnel L, Thorne G et al. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 2014; 58: 3976-82
14. Snydman DR, Jacobus NV, McDermott LA. Activity of a novel cyclic lipopeptide, CB-183, 315, against resistant Clostridium difficile and other Grampositive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother 2012; 56: 3448-52
15. Chilton CH, Crowther GS, Todhunter SL et al. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. J Antimicrob Chemother 2014; 69: 2426-33
16. Boix V, Fedorak RN, Mullane KM et al. Primary outcomes from a Phase 3, randomized, double-blind, active-controlled trial of surotomycin in subjects with Clostridium difficile infection. Open Forum Infect Dis 2017; 4: ofw275
17. Arora V, Kachroo S, Ghantoji SS et al. High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect 2011; 79: 23-6
18. Mehrotra DV, Railkar R. Minimum risk weights for comparing treatments in stratified binomial trials. Stat Med 2000; 19: 811-25
19. Yan X, Su XG. Stratified Wilson and Newcombe confidence intervals for multiple binomial proportions. Stat Biopharm Res 2010; 2: 329-35
20. ZilberbergMD, Reske K, OlsenMet al. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study. BMC Infect Dis 2014; 14: 306
21. Lee CH, Patino H, Stevens C et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomised, controlled, double-blind, non-inferiority, multicentre trial.JAntimicrobChemother 2016; 71: 2964-71
22. Louie TJ, Miller MA, Mullane KMet al. Fidaxomicin versus vancomycin for Clostridium difficile infection.NEngl J Med2011; 364: 422-31
23. Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol 2016; 13: 206-16
24. Jassem AN, Prystajecky N, Marra F et al. Characterization of Clostridium difficile strains in British Columbia, Canada: a shift from NAP1 majority (2008) to novel strain types (2013) in one region. Can J Infect Dis Med Microbiol 2016; 2016: 8207418
25. Cornely OA, Miller MA, Louie TJ et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55 Suppl 2: S154-61
26. Bhavnani SM, Rubino CM, Ambrose PG et al. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data froma randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50: 1568-74
27. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-79
28. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55